Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
Superior survival in diffuse large B cell lymphoma of the bone with immune rich tumor microenvironment
Published in: Blood cancer journal
Access to document
10.1038/s41408-025-01291-z
document
With tumor genomic and gene-expression profiling (GEP), this study investigated the immune-molecular signatures of a unique cohort of diffuse large B-cell lymphoma of the bone (bone-DLBCL), including primary bone (PB-DLBCL, n = 52) and polyostotic-DLBCL (n = 20), in comparison to nodal DLBCLs with germinal center B-cell (GCB) phenotype (nodal-DLBCL-GCB, n = 34). PB-DLBCL and polyostotic-DLBCL shared similar genomic profiles and transcriptomic signatures, justifying their collective analysis as bone-DLBCL. Differential incidences of EZH2, HIST1H1E, and MYC aberrations (p < 0.05) confirmed the distinct oncogenic evolution between bone-DLBCL and...
Ruben A.L. de Groen, Fleur A. de Groot, Stefan Böhringer, Esther J. Kret, Lorraine M. de Haan, Troy Noordenbos, Susan Blommers, Romée E.W. Jansen, Tom van Wezel, Ronald van Eijk, Richard Raghoo, Dina Ruano, Liane te Boome, Valeska Terpstra, Henriette Levenga, Els Ahsmann, Eduardus F.M. Posthuma, Isabelle Focke-Snieders, Lizan Hardi, Wietske C.E. den HartogAnke van den Berg, Pim Mutsaers, King Lam, Marjolein W.M. van der Poel, Myrurgia Abdul Hamid, F. J.Sherida H. Woei-A-Jin, Ann Janssens, Thomas Tousseyn, Judith V.M.G. Bovée, Lianne Koens, Arjan Diepstra, Arjen H.G. Cleven, Marie José Kersten, Patty M. Jansen, Hendrik Veelken, Marcel Nijland, Tim J.A. Dekker, Joost S.P. Vermaat
MATRix and HD-MTX/IFO/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis
Published in: Haematologica
Access to document
10.3324/haematol.2025.287485
document
Fleur A De Groot, Floriske G Stedema, Esther J Kret, Lorraine M De Haan, Patty M Jansen, Stefan Böhringer, Arjan Diepstra, Marjolein W M Van der Poel, Myrurgia Abdul Hamid, Liane C J Te Boome, Valeska Terpstra, Mirian Brink, Hendrik Veelken, Ruben A L De Groen, Tim J A Dekker, Marcel Nijland, Joost S P Vermaat
Non-inferior outcome of abbreviated R-CHOP in patients with stage I primary testicular lymphoma
Published in: European Journal of Cancer
Access to document
10.1016/j.ejca.2025.115776
document
BACKGROUND: Patients with limited-stage primary testicular lymphoma (PTL) typically receive a multimodal regimen, including 6 cycles of R-CHOP, despite limited evidence. In low-risk diffuse large B-cell lymphoma, de-escalation to 4 R-CHOP cycles has proven non-inferior. It remains unclear whether similar de-escalation is feasible in PTL. METHODS: Patients aged ≥ 18 years with Ann Arbor stage I-II PTL diagnosed between 2014 and 2021 were identified in the Netherlands Cancer Registry. Patients receiving ≥ 3 R-CHOP cycles were included. Outcomes were 5-year progression-free survival (PFS), overall survival (OS), and cumulative incidence function...
Diana Al-Sarayfi, Johanna A A Bult, Ruben A L de Groen, Fleur A de Groot, Joost S P Vermaat, Djamilla Issa, Arjan Diepstra, Gerwin Huls, Mar Bellido, Wouter Plattel, Mirian Brink, Marcel Nijland
Serum TARC: a biomarker for early detection or exclusion of relapse in classic Hodgkin Lymphoma
Published in: Blood Advances
Access to document
10.1182/bloodadvances.2025015837
document
Relapsed and refractory peripheral T-cell lymphoma; treatment, challenges and future perspectives
Published in: Leukemia & lymphoma
Access to document
10.1080/10428194.2025.2545927
document
Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of 15 different neoplasms in adults. In Europe and North America, PTCL not otherwise specified (PTCL NOS), nodal T follicular helper lymphoma, angioimmunoblastic type (nTFHL-AI), and anaplastic large cell lymphoma (ALCL) either anaplastic lymphoma kinase (ALK) positive (+) or negative (-) are the most prevalent PTCLs. Relapsed or refractory disease (R/R) is common in PTCL and its management is challenging. Despite response rates and prognoses being disease specific, the outcome of R/R PTCL is dismal except for R/R ALK+ ALCL....
Frederik O Meeuwes, Yasmina I M Serroukh, Marjolein W M van der Poel, Wouter J Plattel, Marcel Nijland